JP2020526525A5 - - Google Patents

Download PDF

Info

Publication number
JP2020526525A5
JP2020526525A5 JP2020500617A JP2020500617A JP2020526525A5 JP 2020526525 A5 JP2020526525 A5 JP 2020526525A5 JP 2020500617 A JP2020500617 A JP 2020500617A JP 2020500617 A JP2020500617 A JP 2020500617A JP 2020526525 A5 JP2020526525 A5 JP 2020526525A5
Authority
JP
Japan
Prior art keywords
rvwf
medicament according
bleeding
subject
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020500617A
Other languages
English (en)
Japanese (ja)
Other versions
JP7307047B2 (ja
JP2020526525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/041320 external-priority patent/WO2019010497A1/en
Publication of JP2020526525A publication Critical patent/JP2020526525A/ja
Publication of JP2020526525A5 publication Critical patent/JP2020526525A5/ja
Priority to JP2023106554A priority Critical patent/JP7641327B2/ja
Application granted granted Critical
Publication of JP7307047B2 publication Critical patent/JP7307047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020500617A 2017-07-07 2018-07-09 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 Active JP7307047B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023106554A JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023106554A Division JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Publications (3)

Publication Number Publication Date
JP2020526525A JP2020526525A (ja) 2020-08-31
JP2020526525A5 true JP2020526525A5 (enExample) 2021-08-12
JP7307047B2 JP7307047B2 (ja) 2023-07-11

Family

ID=63036433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500617A Active JP7307047B2 (ja) 2017-07-07 2018-07-09 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP2023106554A Active JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023106554A Active JP7641327B2 (ja) 2017-07-07 2023-06-29 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療

Country Status (16)

Country Link
US (5) US10632176B2 (enExample)
EP (2) EP3648788B1 (enExample)
JP (2) JP7307047B2 (enExample)
KR (2) KR20260037107A (enExample)
CN (1) CN111436193A (enExample)
AU (2) AU2018298233B2 (enExample)
BR (1) BR112020000321A2 (enExample)
CA (1) CA3069295A1 (enExample)
CO (1) CO2020001322A2 (enExample)
DK (1) DK3648788T3 (enExample)
ES (1) ES2986574T3 (enExample)
FI (1) FI3648788T5 (enExample)
MX (1) MX2025012580A (enExample)
PL (1) PL3648788T3 (enExample)
PT (1) PT3648788T (enExample)
WO (1) WO2019010497A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EA202192140A1 (ru) * 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
US20110072524A1 (en) 2009-08-04 2011-03-24 Baxter International Inc. Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
CN103732244A (zh) 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
FI3648788T5 (fi) 2017-07-07 2024-09-09 Takeda Pharmaceuticals Co Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää

Similar Documents

Publication Publication Date Title
Kumar et al. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
Erhan et al. Ondansetron, granisetron, and dexamethasone compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomized placebo-controlled study
Chinnappa et al. Efficacy of dexmedetomidine with ropivacaine in supraclavicular brachial plexus block for upper limb surgeries
Pereira et al. Effect of preemptive analgesia with ibuprofen in the control of postoperative pain in dental implant surgeries: a randomized, triple-blind controlled clinical trial
JP2016074740A5 (enExample)
Mandal et al. The efficacy of ginger added to ondansetron for preventing postoperative nausea and vomiting in ambulatory surgery
Tanno et al. Therapeutic approach of anaphylaxis
JP2019529541A5 (enExample)
Storms et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis
BR112013010829B1 (pt) Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
Hashimoto et al. Two cases of rocuronium-induced anaphylaxis/anaphylactic shock successfully treated with sugammadex
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
Kundra et al. Comparative study of epidural application of morphine versus gelfoam soaked in morphine for lumbar laminectomy
Sharma et al. The effect of intravenous dexamethasone on intraoperative and early postoperative pain in lumbar spine surgery: a randomized double-blind placebo-controlled study
Shuborna et al. Intra-socket application of Hyaluronic acid reduces pain and swelling following wisdom teeth removal
Ozgul et al. Effect of alkalinisation of lignocaine for propofol injection pain: a prospective, randomised, double-blind study
Moodley Local anaesthetics in dentistry-Part 3: Vasoconstrictors in local anaesthetics
JP2009524612A (ja) 多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用
Pongchairerks et al. Metoclopramide, versus its combination with dexamethasone in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a double-blind randomized controlled trial
Acharya et al. Comparison of equipotent doses of Ramosetron, Ondansetron, and sub-hypnotic dose of Propofol for prevention of postoperative nausea and vomiting in laparoscopic cholecystectomy
Kumar et al. The newer aspect of dexmedetomidine use in dentistry: as an additive to local anesthesia, initial experience, and review of literature
Aslani et al. Clinical results of platelet-rich plasma in frozen shoulder
Entezariasl et al. Efficacy of metoclopramide and dexamethasone for postoperative nausea and vomiting: a double-blind clinical trial
Bakeer et al. Transdermal fentanyl as an adjuvant to paravertebral block for pain control after breast cancer surgery: A randomized, double-blind controlled trial
Jiang et al. Efficacy of continuous intravenous infusion of lidocaine on postoperative sore throat after laryngeal mask insertion: a randomized controlled trial